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OBJECTIVES This study sought to investigate the myocardial and microvascular kinetics of BR14, a novel
third-generation ultrasound contrast agent.
BACKGROUND BR14 produces persistent myocardial opacification after the administration of a single
intravenous bolus when the left ventricular cavity contrast has considerably diminished. The
mechanism of this finding is unknown.
METHODS Nine open-chest dogs with non-critical stenosis of a single coronary artery were given
intravenous bolus injections of BR14 during coronary hyperemia. Time versus acoustic
intensity (AI) plots were generated from the normal and stenosed beds and myocardial blood
flow (MBF) was measured with radiolabeled microspheres. Intravital microscopy was
performed on an exteriorized cremaster muscle in 11 wild-type mice to study the microvas-
cular kinetics of the agent.
RESULTS At peak contrast enhancement, the ratio between AI in the stenosed and normal bed was
0.44  0.23, which was similar to the radiolabeled microsphere-derived MBF ratio between
the two beds (0.45  0.20). At 400 s after injection, the AI ratio between the two beds
approximated unity (0.99 0.07) despite no changes in MBF, indicating redistribution of the
agent. The myocardial kinetics of BR14 was best characterized by a modified lagged normal
density function. Only about 3% of administered microbubbles were estimated to be retained
in the myocardium. Intravital microscopy showed that most of these bubbles were retained
only transiently (2 to 3 s) within capillaries.
CONCLUSIONS BR14 demonstrates redistribution because of transient retention within capillaries. Therefore,
similar to 201Tl, it could potentially be used to detect both coronary stenosis and myocardial
viability after a single injection during stress. (J Am Coll Cardiol 2002;39:530–7) © 2002
by the American College of Cardiology
BR14 is a new ultrasound contrast agent that has undergone
pre-clinical studies and is currently undergoing phase II
studies in humans. It consists of perfluorocarbon-containing
microbubbles stabilized by a phospholipid monolayer (1).
When this agent is injected intravenously as a single bolus
and imaging is initiated several minutes later, persistent
myocardial opacification is noted at a time when the agent
has mostly cleared from the left ventricular (LV) cavity.
This finding implies myocardial retention of at least a
portion of the agent. Our study pursued the following aims:
1) calculation of the myocardial retention fraction of the
agent; 2) modeling of the myocardial kinetics of this agent
in beds supplied by normal coronary arteries and those with
non-critical stenosis; and 3) study of the microvascular
rheology of the agent. For the first two aims we performed
experiments in an open-chest canine preparation. We per-
formed intravital microscopy of the mouse cremaster muscle
for the third aim.
METHODS
The study was approved by the Animal Research Commit-
tee at the University of Virginia and conformed to The
American Heart Association Guidelines for the Use of
Animals in Research.
Canine Experiments
Animal preparation. Nine adult mongrel dogs were used
for the study. They were anesthetized with 30 mg/kg1 of
sodium pentobarbital (Abbott Laboratories, North Chi-
cago, Illinois), intubated and ventilated with room air.
Catheters were placed in both femoral arteries for with-
drawal of reference samples during radiolabeled micro-
sphere injections and in both femoral veins for administra-
tion of drugs, fluids and BR14.
A left lateral thoracotomy was performed, and the heart
was suspended in a pericardial cradle. Catheters were placed
in the aortic root as well as the right and left atria for
pressure measurements. The left atrial catheter was also
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used for the injection of radiolabeled microspheres. The
proximal sections of the left anterior descending coronary
artery (LAD) and left circumflex coronary artery (LCx)
were dissected from the surrounding tissue. Ultrasonic flow
probes (series SC, Transonics, Mount Pleasant, Wimbley,
UK) were placed on both arteries and connected to a digital
flow meter (model T206, Transonics) to monitor epicardial
coronary blood flow. A custom-designed screw occluder was
also placed around the coronary arteries to enable creation of
coronary stenoses of varying severities. A 20-gauge catheter
(Becton-Dickinson) was introduced into the distal branch
of the coronary artery to measure distal coronary pressure
and determine the severity of the stenosis.
Myocardial contrast echocardiography. Myocardial con-
trast echocardiography (MCE) was performed using power
pulse-inversion imaging with a HDI 5000 system (Philips-
ATL, Bothell, Washington). The ultrasound transducer
(transmit frequency of 1.67 and receive frequency of 3.3
MHz) was fixed in position within a saline bath that served
as an acoustic interface between the transducer and the
heart. Imaging was performed at the mid-papillary muscle
short-axis level caudal to the occluder. The transmit power,
image depth and color gains were optimized at the begin-
ning of each experiment and held constant throughout. The
focal plane was placed at the level of the LV posterior wall.
A pulse repetition frequency of 2,500 Hz and a mechanical
index of 0.1 were used. Only end-systolic images (gated to
the T wave on the electrocardiogram) were acquired and
stored digitally using HDI lab. This system allows direct
measurement of AI in linear units before log compression
and post-processing.
BR14 (Bracco Diagnostics, Geneva, Switzerland) was
administered as a controlled 2-ml bolus over 30 s using a
power injector (Medrad, Pittsburgh, Pennsylvania). This is
a third-generation ultrasound contrast agent consisting of
perfluorocarbon-containing microbubbles stabilized by a
phospholipid monolayer. The mean diameter of the micro-
bubbles is 2.5 to 3.0 m, and their mean concentration is 2
to 5  108 ml1 (1). Every end-systolic frame was captured
for the first 30 s after the injection. The pulsing interval was
then increased to every 10 cardiac cycles for 1 min and to
every 20 cardiac cycles for the next 10 min in order to
minimize microbubble destruction. After alignment of all
images from a single injection sequence (2), regions of
interest were placed over the LAD and LCx beds for
measurement of AI, which was then plotted against time.
The resultant curves were smoothed using a moving average
function.
Radiolabeled microsphere analysis. Myocardial blood
flow (MBF) was measured using left atrial injections of
2  106–11 m radiolabeled microspheres (Dupont
Medical Products, Wilmington, Delaware) suspended in 4
ml of 0.9% saline and 0.01% Tween-80. Duplicate arterial
reference blood samples were collected from the femoral
arteries. At the end of the experiment, the post-mortem LV
short-axis slice corresponding to the MCE image was cut
into 16 wedge-shaped pieces, and each piece was further
divided into epi-, mid- and endocardial portions. The tissue
and blood samples were counted in a gamma well scintilla-
tion camera with a multichannel analyzer (model 1282,
LKB Wallace, Washington, DC), and corrections were
made for activity spilling from one energy window to
another with custom-designed software (3).
Myocardial blood flow to each segment was calculated
from the equation Qm(Cm·Qr)/Cr where Qm is blood flow
to the segment (ml/min1), Cm is tissue counts, Qr is the
rate of arterial blood sample withdrawal (ml/min1) and Cr
is arterial reference sample counts (4). Transmural MBF
(ml/min1/g1) to each of the 16 wedge-shaped pieces was
calculated as the quotient of the summed flows to the
individual segments within that piece and their combined
weight. Mean MBF to both beds were then calculated by
averaging the transmural MBF in all segments in those
beds.
Experimental protocol. Noncritical stenoses of varying
severities (judging from the trans-stenotic pressure gradient)
were placed on either the LAD or LCx. Maximal coronary
hyperemia was induced with a continuous infusion of 1
g/kg1/min1 of a selective adenosine A2a receptor
agonist-2-cyclohexyl-methyl-idenehydrazino-adenosine
(WRC-0470). Radiolabeled microspheres were injected, a
bolus of BR14 was administered, and MCE was performed.
Post-mortem, the heart slice corresponding to the MCE
image was removed for tissue staining for presence of
infarction and radiolabeled microsphere MBF analysis.
Intravital Microscopy Experiments
Animal preparation. Eleven mice were anesthetized with
an intraperitoneal injection (12.5 l/g1) of a solution
containing ketamine hydrochloride, xylazine and atropine.
Body temperature was maintained at 37°C with a heating
pad. A jugular vein was cannulated for the administration of
microbubbles and drugs. The right or left cremaster muscle
was exteriorized, a longitudinal incision was made in it, and
the edges were secured to a translucent custom-designed
stage. The preparation was superfused continuously with
isothermic bicarbonate-buffered saline (5).
Intravital microscopy was performed with an
Axioskop2-FS microscope (Carl Zeiss, Inc., Thornwood,
New York) using a saline immersion objective (X20/0.5
N.A., X40/0.8 N.A. or X 63/0.9 N.A.) under combined
Abbreviations and Acronyms
AI  acoustic intensity
LAD  left anterior descending coronary artery
LCx  left circumflex coronary artery
LNDF  lagged normal density function
LV  left ventricular
MBF  myocardial blood flow
MCE  myocardial contrast echocardiography
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trans- and fluorescent epi-illumination with a 469–500 nm
excitation filter. Video recordings were made with a high-
resolution charge-coupled device camera (C2400, Ham-
mamatsu Photonics, Bridgewater, New Jersey) interfaced
with a video time display unit and connected to an S-VHS
recorder.
Arteriolar blood velocities were measured with a dual-slit
photodiode (6) and converted to mean blood velocities (Vb)
by multiplication by 0.625 (7). Shear rates (w) were
determined by w  2.12(8 Vb)/d, where d is the vessel
diameter and 2.12 is a correction factor for the shape of the
velocity profile.
Experimental protocol. Video recordings of arterioles
feeding the tissue were made, and their diameter and blood
velocity measurements were calculated at baseline. Approx-
imately 4  107 fluorescently labeled microbubbles (provid-
ed by the manufacturer) were then injected intravenously as
a slow bolus. In five mice, random optical fields were
observed at 40 and 63 for 30 min to determine the fate
of the microbubbles. In three mice, 20 optical fields (40)
were sequentially observed at 2, 10, 20 and 30 min to
determine the temporal behavior of the initially stationary
bubbles. In three additional mice, the preparation was
observed continuously for 20 min under 20 objective. The
arrival times and durations of retention were recorded for
each microbubble. Video recordings as well as arteriolar
velocity and diameter measurements were repeated at 10-
min intervals.
Statistical Methods
Data are expressed as mean  1 standard deviation. Dif-
ferences between 2 stages were assessed using analysis of
variance. When differences were found, any two stages were
compared using Student’s t test with Bonferroni correction.
Correlations were calculated using least-fit regression anal-
yses. Differences were considered significant at p  0.05
(two-sided).
RESULTS
Canine Experiments
Figure 1 illustrates a time-versus-AI plot from the LAD
and LCx beds from a dog with a non-critical LAD stenosis
during maximal hyperemia induced by WRC-0470. The
initial and delayed images are also shown. The AI in the
stenosed bed is less than the normal bed during the peak
contrast effect of BR14, a finding that has been reported for
all intravenous ultrasound contrast agents. The unique
findings of BR14 are that myocardial opacification persists
at a time when microbubbles have all but cleared from the
LV cavity and that, despite ongoing hyperemia, the AI in
both beds becomes identical over time. This latter finding is
very similar to that seen after 201Tl injection and is termed
“redistribution” (8). That is, there is faster washout of the
tracer from the bed with higher initial microbubble concen-
tration and slower washout from the bed with lower initial
microbubble concentration. Although there is less hyper-
Figure 1. Changes in acoustic intensity (AI) values from the left anterior descending coronary artery (LAD) and left circumflex coronary artery (LCx) beds
(denoted on the images) after the injection of BR14 during maximal hyperemia. The LAD had a non-critical stenosis, whereas the LCx bed was normal.
Although a flow mismatch is seen early after injection, the AI in both beds is similar at a later point in time, indicating redistribution. See text for details.
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emic flow in the region showing less AI initially, the
presence of redistribution indicates that the myocardium
distal to the stenosis is normal (not infarcted) (8).
At peak contrast enhancement, the ratio between AI in
the stenosed and normal bed in all nine dogs was 0.44 
0.23, which was similar to the radiolabeled microsphere-
derived MBF ratio between the two beds (0.45  0.20).
Despite no change in MBF in the two beds, however, the
AI ratio 400 s later between the two beds was 0.99  0.07,
indicating redistribution of BR14. No infarction was seen in
these dogs on post-mortem tissue staining.
Intravital Microscopy
Microbubble injections were well tolerated in all mice, and
no significant changes in arteriolar flow or shear rates were
observed after injection (Table 1). Within 2 min of injec-
tion, stationary microbubbles (defined as those retained at a
single site for 5 s) were observed in both capillaries and
venules. The number of the injected microbubbles that were
stationary was very small compared with the number show-
ing normal flux. Early after injection, most stationary
microbubbles appeared to be lodged in capillaries, whereas
by 30 min most stationary microbubbles were found in
venules (Fig. 2). Venular retention resulted from the adher-
ence of microbubbles to activated leukocytes, which has
been seen in this experimental model with other agents as
well (8) and can, in part, be explained by activation of
leukocytes from surgical trauma (5).
The unique feature of BR14 is its retention within the
capillaries, which has the following characteristics. First,
very few of the injected bubbles are retained in the capil-
laries (Fig. 3). Second, this retention is transient. Figure 4
illustrates the time course of individual bubble retention
from a single experiment when continuous observations
were made at 20 magnification. Third, the stationary
microbubbles retain a uniform spherical shape and, unlike
other bubbles, produce no distortion of the capillaries in
which they were retained. Fourth, the diameter of stationary
microbubbles does not change over time (3.9  0.5 m vs.
4.6  0.7 m for observations at 0 to 10 and 10 to 20 min,
p  0.42), indicating that neither entrapment nor dislodg-
ment is related to bubble size. Fifth, in the majority of cases,
microbubble retention in a capillary results in temporary
cessation of red cell flux through that vessel, although slow
red blood cell flux can still persist around the microbubble.
Sixth, the dislodged microbubbles are frequently observed to
stagger through the capillaries, which is also seen with freely
circulating microbubbles with retention times 5 s. Finally,
microbubbles that persist for more than 20 min are com-
monly phagocytosed by leukocytes resident within the
capillaries, resulting in restoration of red blood cell flux.
DISCUSSION
We have described the myocardial and microvascular kinet-
ics of BR14, a novel third-generation ultrasound contrast
agent. We believe that the unique properties of this agent
will allow it to be used like 201Tl. That is, after a single
injection at peak stress, early and delayed images will
provide information on both the presence of coronary
stenoses as well as myocardial viability. Because of its
myocardial retention, we believe that this agent could be
used during exercise stress with imaging performed after the
stress protocol is complete. This agent could, therefore, not
only provide information on myocardial perfusion but also
enhance regional function assessment during exercise stress.
Myocardial kinetics of BR14. Because the lung acts as a
large mixing chamber, a venous bolus injection of a contrast
agent will spread in a normal or Gaussian form when the
contrast reaches the coronary arteries (Fig. 5A). This
Gaussian input function is of the form
G(t)
A
2  e

1
2 t2
where A is the area under the curve that depends on the
amount of contrast injected, and  is the width of the curve,
which depends mostly on cardiac output if duration of
injection is short.
The output function of the mixing chamber in this model
can be derived by two methods. One can either use a
Table 1. Arteriolar Dimension and Hemodynamic Data From Intravital Microscopy
Experiments
2 min 10 min 20 min 30 min
Arteriolar diameter (m) 36.9  6.3 23.8  8.5 27.4  17.4 27.1  16.1
Arteriolar blood velocity (mms1) 9.3  2.7 10.0  2.6 9.3  5.9 8.8  5.8
Wall shear rate (s2 [103]) 2.7  0.6 4.7  1.3 4.1  1.7 3.7  1.2
Figure 2. Location and average numbers of stationary microbubbles per 20
high power optical fields (OF) over time. See text for details.
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convolution of the input and transfer functions (9) or solve
the following differential equation:
dc
dt
 k(G t  C t)
where
 
F
V
(V is the volume of the mixing chamber, F is the flow
through it, and Ct is the concentration of contrast in the
myocardium). The solution to this equation, which does not
have an analytic form, is termed a lagged-normal density
function (LNDF) (10) and is obtained with intravenous
contrast agents that are not retained within the myocardium
(Fig. 5B) (11).
If after administration, all microbubbles were retained
within the myocardium (as in the case of radiolabeled
microspheres), the AI would be represented by the integral
of a LNDF (LNDFi). If only a fraction (f1) of the
microbubbles are retained (Fig. 1), the resulting AI attrib-
utable to retained bubbles can be given by
f 1·f 2) LNDF i
where f 2 is the myocardial blood volume fraction (percent of
myocardial mass that is blood).
Therefore, the AI due to both stuck and free bubbles is
given by
LNDF  f·LNDFi
where
f  f1·f2
This model accurately fits the experimental time-
versus-AI curves generated in the open-chest dogs (Fig. 6).
On the basis of this model, the fraction of BR14 being
retained in the myocardium is very small (3%).
Comparison with other contrast agents. Most second-
generation ultrasound contrast agents behave like red blood
cells in vivo and are not retained in the normal microcircu-
lation (8,12,13). Myocardial redistribution of an ultrasound
contrast agent in normal myocardium was first reported
with AIP-201, a 10 m air-filled bubble with a thick
albumin shell (14). Because of its size, this agent could be
injected only into the arterial system. It was found that
during coronary occlusion, a left atrial injection of this agent
Figure 3. Example of retained microbubbles within the capillaries under fluorescent epi-illumination. Microbubble (A) on the left of the picture remains
static throughout the imaging sequence. A second microbubble (B) can be seen to stop in an adjacent capillary, remains virtually static for 4 s and then
dislodges.
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resulted in no opacification of the occluded bed, but
opacification was noted within minutes after perfusion was
re-established, without performing a second injection of
contrast, and at a time when there was no contrast in the LV
cavity. Subsequently, using intravital microscopy, we found
that these bubbles entered arterioles supplying the occluded
bed via collateral channels. When flow was re-established,
the bubbles dislodged from these feeding arterioles and
went to regions with adequate microvascular flow. We
found that redistribution occurred only to normal, non-
infarcted tissue and not to infarcted regions with no reflow
(14). Because of the limited use of ultrasound contrast
agents in the cardiac catheterization laboratory, however,
AIP-201 is no longer under clinical development.
Persistent myocardial opacification from a single venous
injection was also seen with Echogen, an ultrasound con-
trast agent produced using the “phase shift” technology,
where a liquid at room temperature turns to gas at body
temperature (15). The problem with this agent was that the
size of the microbubble could not be controlled in vivo and
Figure 4. A graphic representation of the temporal course of transient retention (arrival and departure times) of individual microbubbles in capillaries at
20 magnification. It can be seen that the microbubbles responsible for the acoustic signal at any given time are different.
Figure 5. A mixing chamber model for the coronary circulation illustrating the input and output functions of a venous bolus injection of a second-generation
contrast agent that is not retained within the myocardium. The input function resembles a Gaussian function, whereas the output function resembles a
lagged normal density function. See text for details.
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the microbubbles became larger in blood from diffusion of
air normally present in blood into the non-encapsulated
perfluorocarbon emulsion. This agent also caused comple-
ment activation. Because of safety concerns, this agent is
also no longer in clinical development.
BR14 overcomes the problems associated with its two
predecessors. First, it consists of stabilized microbubbles of
a small size (1). All pre-clinical studies have attested to the
safety of this agent administered in very large amounts to
animals. Second, unlike the larger bubbles that were en-
trained within larger vessels (arterioles and venules), these
microbubbles are transiently retained within capillaries.
Therefore, their presence in capillaries minutes after injec-
tion indicates capillary viability. Third, its kinetics are
identical to 201Tl, an agent that has been used clinically for
more than 20 years and has provided important information
in patients with coronary artery disease. Thus a clinical
paradigm already exists for its use.
From this study, we cannot explain the mechanism of
transient microbubble retention within the capillaries. It
cannot be explained on the basis of size, because these
bubbles do not seem to plug capillaries. Instead, they are
transiently retained before dislodgment, with no change in
capillary dimensions either at or proximal to the site of
entrapment. Another mechanism may be a rigid shell
preventing easy capillary passage. This is unlikely because
these bubbles have successfully transited the pulmonary
circulation and dislodge easily from the site of capillary
retention. Bubble charge and coating characteristics are
other factors that are under investigation in our laboratory.
Finally, the results of findings in the skeletal muscle may not
completely explain those noted in the beating canine heart.
Clinical implications. It is obvious from our results that
only a fraction of the microbubbles is retained within the
myocardium. Myocardial opacification, therefore, is orders
of magnitude lower in delayed compared with initial images
(Fig. 1). We therefore propose the following imaging
protocol with this agent. The initial images should be
obtained using low-mechanical-index intermittent imaging
(once every cardiac cycle). Both the low-power and inter-
mittent protocols will minimize microbubble destruction.
The delayed image should be obtained using a high me-
chanical index. In this manner, myocardial signal will be
good in the delayed image despite a lower number of
bubbles present in the myocardium. These images could
then be displayed side by side as shown in Figure 1. Because
a number of images would have been recorded, time-
versus-AI plots from several beds could also be derived.
We feel that that the best application of this imaging
protocol would be during exercise stress where a single
injection could be performed at peak stress. Initial images
could then be obtained within 1 to 3 min after cessation of
exercise, and delayed images could be obtained 5 to 7 min
later. If the delayed images are inadequate, a second
injection of the agent could be made at rest. This protocol
would therefore address both coronary disease detection and
myocardial viability from a single bolus injection. The mode
of administration (bolus rather than continuous infusion
[3]) is also suitable for exercise, compared with other forms
of stress.
Figure 6. Time-versus-acoustic intensity plots of BR14 from the left anterior descending coronary artery (LAD) and left circumflex coronary artery beds
in the presence of non-critical LAD stenosis during hyperemia. The proposed model fits the plots from both the beds. See text for details. Abbreviations
as in Figure 1.
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